Sanofi Beats Novo to Buy Ablynx for $4.8 Billion Sanofi Beats Novo to Buy Ablynx for $4.8 Billion

French drugmaker Sanofi has agreed to buy Belgian biotech company Ablynx for 3.9 billion euros ($4.8 billion), beating Novo Nordisk and marking its second big deal this month after buying Bioverativ.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news